0P
0PT.F Prothena Corporation plc
- Market cap
- EUR 391M
- P/E
- -
- P/B
- 1.64x
- ROE
- -1.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0PT.F undervalued?
Graham numberThe Graham number of Prothena Corporation plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prothena Corporation plc fundamental analysis
No fundamental analysis for Prothena Corporation plc yet.
Prothena Corporation plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial fo…
Full company profileProthena Corporation plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Prothena Corporation plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.06M | 27.5M | 955K | 814K | 853K | 201M | 53.9M | 91.4M | 135M | 9.68M | 70.3M |
| Gross Profit | -118M | -107M | -100M | -50.0M | - | - | - | - | - | - | - |
| Operating Income | -160M | -155M | -143M | -85.8M | -113M | 72.0M | -132M | -191M | -155M | -185M | -15.1M |
| EBITDA | - | -151M | -149M | -70.5M | -106M | - | -131M | -190M | -154M | -184M | -14.3M |
| Net Income | -160M | -153M | -156M | -77.7M | -111M | 67.0M | -117M | -147M | -122M | -244M | -3.16M |
| EPS | - | -3.98 | -3.90 | -1.95 | -2.78 | 1.43 | -2.24 | -2.74 | -2.27 | -4.53 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 460M | 496M | 499M | 419M | 333M | 609M | 758M | 696M | 547M | 327M | 284M |
| Total Liabilities | 94.6M | 89.1M | 176M | 146M | 149M | 143M | 136M | 135M | 60.2M | 46.3M | 14.7M |
| Shareholders' Equity | 365M | 407M | 323M | 273M | 184M | 466M | 622M | 561M | 487M | 280M | 269M |
| Cash & Short-term Investments | 387M | 418M | 428M | 376M | 295M | 579M | 710M | 619M | 471M | 308M | 271M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -116M | -131M | -28.3M | -53.0M | -80.4M | 92.6M | -109M | -87.8M | -150M | -164M | -10.8M |
| Capital Expenditure | 16.6M | 3.63M | 1.77M | 555K | 196K | 575K | 464K | 1.41M | 298K | 138K | 97.3K |
| Free Cash Flow | - | -135M | -30.0M | -53.5M | -80.6M | 92.0M | -109M | -89.3M | -150M | -164M | -11.8M |
| Ratios | |||||||||||
| ROE | -43.8% | -37.6% | -48.2% | -28.5% | -60.4% | 14.4% | -18.8% | -26.2% | -25.1% | -87.0% | -1.2% |
| ROA | -34.8% | -30.9% | -31.2% | -18.5% | -33.4% | 11.0% | -15.4% | -21.1% | -22.4% | -74.7% | -1.1% |
| Net Profit Margin | -15,176.1% | -556.8% | -16,297.9% | -9,542.6% | -13,029.8% | 33.4% | -217.0% | -160.9% | -90.5% | -2,520.6% | -4.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Prothena Corporation plc dividends
Prothena Corporation plc has not paid dividends in the last 9 fiscal years.
Who owns Prothena Corporation plc
- Insiders 23.95%
- Institutions 76.05%
- Public & others 0.00%
- Shares outstanding 51.3M
- Free float 33.4M
Prothena Corporation plc company profile
- Company name
- Prothena Corporation plc
- Ticker
- 0PT.F
- ISIN
- IE00B91XRN20
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 67
- Fiscal year end
- December
- Address
- 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
- Phone
- 353 1 236 2500
- Website
- prothena.com
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc management
9- Dr. Gene G. Kinney Ph.D.President, CEO & Director · born 1969
- Mr. Tran B. Nguyen M.B.A.Chief Financial Officer · born 1974
- Mr. Brandon S. SmithChief Operating Officer · born 1975
- Dr. Wagner M. Zago Ph.D.Chief Scientific Officer · born 1973
- Ms. Karin L. Walker CPAChief Accounting Officer & Controller · born 1963
- Mr. Mark C. Johnson C.F.A.Vice President of Investor Relations
- Mr. Michael J. IsaacsGeneral Counsel & Corporate Secretary
- Phillip DolanSr. Director & Head of Exploratory Research
- Ms. Annie Evans KingstonChief Strategy Officer